Lawrence Blacher, M.D., Memorial Lecture: Advancing the Fight Against Cardiac Amyloidosis: A 2026 Update - Scorecard - MDSpire

Lawrence Blacher, M.D., Memorial Lecture: Advancing the Fight Against Cardiac Amyloidosis: A 2026 Update

Please join us to hear Omar F. Abou-Ezzeddine, M.D.C.M., M.S., at the Lawrence Blacher, M.D., Memorial Lecture, where he will provide a 2026 update on amyloid cardiomyopathy, highlighting current diagnostic strategies, emerging therapies, and practical approaches to patient care.

  • By

  • March 20, 2026

  • 1 min

Share

Clinical Scorecard: Lawrence Blacher, M.D., Memorial Lecture: Advancing the Fight Against Cardiac Amyloidosis: A 2026 Update

At a Glance

CategoryDetail
ConditionCardiac Amyloidosis
Key MechanismsInvolves deposition of amyloid proteins in the heart, leading to heart failure and cardiomyopathy.
Target PopulationPatients with heart failure and cardiomyopathy due to amyloid deposition.
Care SettingHospital and outpatient settings.

Key Highlights

  • Increasing recognition of cardiac amyloidosis as a treatable cause of heart failure.
  • Advancements in imaging and biomarkers for diagnosis.
  • Emerging therapies for disease modification.
  • Importance of early recognition and supportive management.
  • Current strategies for patient care in amyloid cardiomyopathy.

Guideline-Based Recommendations

Diagnosis

  • Utilize current and emerging diagnostic and imaging strategies.

Management

  • Apply supportive management strategies for patient care.

Monitoring & Follow-up

  • Evaluate the effectiveness of disease-modifying therapies.

Risks

  • Consider risks associated with amyloid deposition in the heart.

Patient & Prescribing Data

Individuals diagnosed with amyloid cardiomyopathy.

Focus on both supportive care and disease-modifying therapies.

Clinical Best Practices

  • Early recognition of cardiac amyloidosis is crucial.
  • Incorporate advanced imaging techniques in diagnosis.
  • Stay updated on emerging therapies and management strategies.

References

    Original Source(s)

    Lawrence Blacher, M.D., Memorial Lecture: Advancing the Fight Against Cardiac Amyloidosis: A 2026 Update

    • by

    • March 20, 2026

    Related Content

    Safety and efficacy of sacubitril/valsartan vs. benazepril administered as initial treatment for STEMI patients with mid-range ejection fraction: a propensity score matching analysis

    Independent prognostic value of the triglyceride–glucose index and its incremental predictive contribution beyond traditional risk markers in acute heart failure: a retrospective cohort study

    Pulmonary vein stenosis after pediatric heart transplantation: incidence and risk factors